HEGGIE THERESA

SEC Form 4 insider trading activity

HEGGIE THERESA has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 15, 2026.

On the most recent filing, HEGGIE THERESA is listed as Director at BIOCRYST PHARMACEUTICALS INC. Inside the rolling window, HEGGIE THERESA reported no open-market purchases and 1 open-market sale totaling $505K in BCRX.

Companies traded

Other insiders at BCRX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$505K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
BCRX
HEGGIE THERESA
Sale$505KMar 24SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has HEGGIE THERESA made?

HEGGIE THERESA has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.

Which companies does HEGGIE THERESA trade?

HEGGIE THERESA has filed SEC Form 4 disclosures for 1 company, including BCRX.

When was HEGGIE THERESA's most recent SEC Form 4 filing?

HEGGIE THERESA's most recent SEC Form 4 filing on Tracefour is dated Jun 15, 2026.

What is HEGGIE THERESA's total buy and sell value in the current window?

Inside the rolling retention window, HEGGIE THERESA bought $0 and sold $505K based on SEC Form 4 filings.

What was HEGGIE THERESA's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 49,933 BCRX shares on 2026-03-20, worth $505K, per SEC Form 4 filings.